ArticleCureus2026
Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) plus sodium-glucose cotransporter 2 inhibitor (SGLT2i) group shows a lower risk of major adverse cardiovascular events (MACE), admission due to heart failure (HF), and worsening chronic kidney disease (CKD), as determined by exploratory analysis; however, statistical superiority criteria were not met. The major cause of mortality in patients with diabetes is cardiovascular disease, and it is crucial to address this burden. This study evaluated the cardiovascular effects of combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with sodium-glucose cotransporter 2 inhibitors (SGLT2is) versus either drug alone in patients with type 2 diabetes (T2D). This retrospective cohort study used data from 238 patients with a diagnosis of T2D aged 18 years or older who were followed for at least four years by the Endocrinology Department at Hospital Divino Espírito Santo, Ponta Delgada, Portugal. We included individuals who were treated for at least one year with a combination of GLP-1 RA and SGLT2i (n=99), compared with GLP-1 RA monotherapy (n=61) and SGLT2i monotherapy (n=78). The primary outcome was the reduction of major adverse cardiovascular events. The secondary outcomes were the reduction of worsening chronic kidney disease, the reduction of admissions due to heart failure, and the safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.